Baker Bros Reveals New Stake in Aquinox Pharmaceuticals (AQXP)

In a new filing with the SEC, Julian Baker and Felix Baker’s Baker Bros. Advisors revealed new stake in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP). In Aquinox Pharmaceuticals, Baker Bros currently owns a total of 1.2 million shares, which make the holding equal to 12.1% of the common stock.

Pharmacyclics, Inc. (NASDAQ:PCYC)

Aquinox Pharmaceuticals, Inc (NASDAQ:AQXP) is a clinical-stage pharmaceutical company which discovers and develops novel drugs candidates for the treatment of inflammation and cancer.

Last month, the company closed its initial public offering of approximately 4.8 million shares at an offer price of $11.0 per share, which included 630,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. The total offering price is an estimated $53.1 million, excluding underwriting discounts, estimated expenses and commissions. This month, Zacks initiated coverage on Aquinox with a ‘Hold’ rating. Another analyst, Cowen and Company, initiated coverage on Aquinox Pharmaceuticals, Inc (NASDAQ:AQXP) with an ‘outperform’ recommendation at a target price of $30.0 per share.

Baker Bros Advisors, LLC, is located in New York and is a privately owned hedge fund. The fund has an equity portfolio of $7.1 billion, concentrated in the Healthcare sector. It was founded in the year 2000 by Felix Baker and Julian Baker. Dr. Felix J. Baker, who holds a B.S. in Biology and Ph.D in Immunology from Standford University, serves as the Managing Member of the fund. Co-founder, Julian C. Baker holds an A.B. Magna Cum Laude from the Harvard University, also serves as the managing member of the fund.

Baker Bros Advisors has been active until last month, reporting new and tweaked stakes in several companies. Last month, the fund upped positions in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to 20.5 million shares and in Synageva Biopharma Corp (NASDAQ:TRMS) to 8.2 million shares. In January, Baker Bros disclosed holding 13.8 million shares in Genomic Health, Inc. (NASDAQ:GHDX) and 5.3 million shares in Celsus Therapeutics PLC (ADR) (OTCMKTS:CLSXD).

According to the fund’s latest 13F, top holdings of Baker Bros, as at the end of last year, were Pharmacyclics Inc (NASDAQ:PCYC), with a stake valued in excess of $922.3 million, followed by Seattle Genetic Inc. (NASDAQ:SGEN), of which it held around 20.7 million shares worth $827.2 million, and Incyte Corp (NASDAQ:INCY), in which it owned 14.8 million shares valued at more than $749.9 million.

Disclosure: none

Recommended Reading:

Southpoint Capital Advisors Ups Interest in Nexstar Broadcasting Group, Inc. (NXST)

Deerfield Management Boosts Stake In Insmed Incorporated (INSM)

Adage Capital and Maverick Capital are Bullish on Castlight Health Inc (CSLT)

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!